In recent years, numerous epidemiological studies have reported a rising incidence of cardiovascular disease in patients with comorbid course of non-alcoholic fatty liver disease and cardiovascular diseases, which is the main cause of death of these patients. The purpose of the study was to establish the clinical and biochemical features of the course of non-alcoholic steatohepatitis (NASH) with comorbid obesity of I-II degree and coronary heart disease (CHD) compared with the course of NASH on the background of obesity without comorbid CHD. Material and methods. We examined 86 patients with NASH. 30 patients with NASH and obesity of I-II degree (group 1), 56 patients with NASH, comorbid obesity of I-II degree and CHD (stable angina pectoris of I-II functional classes) (group 2). To determine the dependence of the course of NASH with CHD, the groups of patients were randomized according to age, sex and degree of obesity. The average age of patients was 55.9 ± 5.68 years. The control group consisted of 30 practically healthy persons of the corresponding age. Results and discussion. The obtained results showed that the clinical picture of NASH was characterized by multi symptoms of manifestations and low intensity of clinical manifestation of syndromes with predominance of astheno-vegetative, dyspeptic syndromes, hepatomegaly, hyper- and dyslipidemia, insulin resistance on the background of mild cytolysis and mesenchymal inflammation. During ultrasonographic examination of the liver in patients with NASH, we detected hepatomegaly, medium-grained transformation and hyperechogenicity of the liver parenchyma, dorsal fading of echoes as a result of diffuse fatty infiltration, visual impairment of the intrahepatic vessels and diaphragm. Conclusion. The main factors of the development and progression of NASH on the background of comorbid CHD are the violation of the lipid profile of the blood (increase in the content of total cholesterol, triglycerides, proatherogenic fraction of low density lipoproteins on the background of reduction of anti-atherogenic high-density lipoproteins) and glucose metabolism (postprandial hyperglycemia, insulin resistance) which ultimately promote the early development of adverse cardiovascular events.

Keywords: nonalcoholic steatohepatitis, coronary heart disease, insulin resistance, dyslipidemia, cytolysis

Full text: PDF (Ukr) 209K

1. Khukhlina OS, Drozd VIu. Optymizatsiia likuvannia nealkoholnoho steatohepatytu u khvorykh na ozhyrinnia ta ishemichnu khvorobu sertsia. [Optimization of treatment of nonalcoholic steatohepatitis in obese patients and coronary heart disease]. Liky Ukrainy. 2016; 9(205): 46-52. [Ukrainian]
2. Khukhlina OS, Antoniv AA, Mandryk OIe, Hryniuk OIe. Nealkoholna zhyrova khvoroba pechinky ta komorbidni stany: osoblyvosti patohenezu, kliniky, diahnostyky, likuvannia [Non-alcoholic fatty liver disease and comorbid conditions: peculiarities of pathogenesis, clinic, diagnosis, treatment]. Chernivtsi; 2017. 205 p. [Ukrainian]
3. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65: 1038-48. https://www.ncbi.nlm.nih.gov/pubmed/26823198. https://doi.org/10.1016/j.metabol.2015.12.012
4. Castera L. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015; 35(3): 291-303. https://www.ncbi.nlm.nih.gov/pubmed/26378645. https://doi.org/10.1055/s-0035-1562948
5. Pais R, Giral P, Khan JF, Rosenbaum D, Housset C, Poynard T, Ratziu V. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016; 65: 95-102. https://www.ncbi.nlm.nih.gov/pubmed/27129836. https://doi.org/10.1016/j.jhep.2016.02.023
6. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017; 8(2): 51-8. https://www.ncbi.nlm.nih.gov/pubmed/28573067. https://www.ncbi.nlm.nih.gov/pmc/articles/5437502. https://doi.org/10.4291/wjgp.v8.i2.51
7. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. American Association for the Study of Liver DiseasesUnited States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015; 61: 1390-405. https://www.ncbi.nlm.nih.gov/pubmed/25557690. https://www.ncbi.nlm.nih.gov/pmc/articles/4900161. https://doi.org/10.1002/hep.27678
8. Targher G, Byrne CD, Lonardo A, Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3): 589-600. https://www.ncbi.nlm.nih.gov/pubmed/27212244. https://doi.org/10.1016/j.jhep.2016.05.013
9. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease − meta-analytic assessment of preva-lence, incidence, and outcomes. Hepatology. 2016; 64: 73-84. https://www.ncbi.nlm.nih.gov/pubmed/26707365. https://doi.org/10.1002/hep.28431
10. Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, et al. Diagnostic value of a computerized hepatorenal index for sonographic quanification of liver steatosis. Am J Roentgenol. 2009; 192(4): 909-14. https://www.ncbi.nlm.nih.gov/pubmed/19304694. https://doi.org/10.2214/AJR.07.4016
11. Wree A, Mehal WZ, Feldstein AE. Targeting cell death and sterile inflammation loop for the treatment of non-alcoholic steatohepatitis. Semin Liver Dis. 2016; 36(1): 27-36. https://www.ncbi.nlm.nih.gov/pubmed/26870930. https://www.ncbi.nlm.nih.gov/pmc/articles/4955833. https://doi.org/10.1055/s-0035-1571272